Cargando…
Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
BACKGROUND: The changes in the platelet-to-lymphocyte ratio (PLR) before and after recombinant tissue plasminogen activator (rtPA) treatment and the time point at which the PLR is a potentially valuable prognostic predictor in patients wit ischemic stroke remain largely unknown. Therefore, the purpo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549955/ https://www.ncbi.nlm.nih.gov/pubmed/36225933 http://dx.doi.org/10.3389/fimmu.2022.1000626 |
_version_ | 1784805785653477376 |
---|---|
author | Sun, Ying-Ying Wang, Mei-Qi Wang, Yan Sun, Xin Qu, Yang Zhu, Hong-Jing Wang, Si-Ji Yan, Xiu-Li Jin, Hang Zhang, Peng Yang, Yi Guo, Zhen-Ni |
author_facet | Sun, Ying-Ying Wang, Mei-Qi Wang, Yan Sun, Xin Qu, Yang Zhu, Hong-Jing Wang, Si-Ji Yan, Xiu-Li Jin, Hang Zhang, Peng Yang, Yi Guo, Zhen-Ni |
author_sort | Sun, Ying-Ying |
collection | PubMed |
description | BACKGROUND: The changes in the platelet-to-lymphocyte ratio (PLR) before and after recombinant tissue plasminogen activator (rtPA) treatment and the time point at which the PLR is a potentially valuable prognostic predictor in patients wit ischemic stroke remain largely unknown. Therefore, the purpose of this study was to explore the characteristics of the PLR and evaluate their effects on clinical outcomes before and 24 h after rtPA treatment. METHODS: This study included 741 consecutive patients with acute ischemic stroke who underwent intravenous thrombolysis with rtPA. We collected data on demographics, vascular risk factors, medication history, and other clinical information pertaining to all patients. Specifically, blood samples for PLR measurement were collected on admission and 24 h after stroke. The outcome was assessed by using the Modified Rankin Scale (mRS) at 3 months and whether death occurred within 3 months or not. Univariate and multivariate logistic regression analysis was used to assess the association of the PLR with the risks of poor outcome (mRS>2) and death. An individualized prediction model was established to predict poor outcome. RESULTS: Of the 741 patients, 255 (34.4%) had poor outcome, and 43 (5.8%) died. The PLR significantly increased 24 h after rtPA in patients with poor outcome and death. Logistic analysis revealed that higher PLR 24 h after rtPA was independently associated with increased risks of poor outcome and death. However, the PLR on admission was not associated with the risks of poor outcome and death. The individualized prediction model for poor outcome based on the 24-h PLR exhibited favorable discrimination (areas under the curves of the training and validation groups: 0.743 and 0.729, respectively), calibration (P > 0.05), and clinical usefulness. CONCLUSIONS: We found the PLR to be a variable that potentially predicts the risks of poor outcome and death in patients with acute ischemic stroke 24 h after rtPA; however, it cannot make the same prediction on admission. |
format | Online Article Text |
id | pubmed-9549955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95499552022-10-11 Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients Sun, Ying-Ying Wang, Mei-Qi Wang, Yan Sun, Xin Qu, Yang Zhu, Hong-Jing Wang, Si-Ji Yan, Xiu-Li Jin, Hang Zhang, Peng Yang, Yi Guo, Zhen-Ni Front Immunol Immunology BACKGROUND: The changes in the platelet-to-lymphocyte ratio (PLR) before and after recombinant tissue plasminogen activator (rtPA) treatment and the time point at which the PLR is a potentially valuable prognostic predictor in patients wit ischemic stroke remain largely unknown. Therefore, the purpose of this study was to explore the characteristics of the PLR and evaluate their effects on clinical outcomes before and 24 h after rtPA treatment. METHODS: This study included 741 consecutive patients with acute ischemic stroke who underwent intravenous thrombolysis with rtPA. We collected data on demographics, vascular risk factors, medication history, and other clinical information pertaining to all patients. Specifically, blood samples for PLR measurement were collected on admission and 24 h after stroke. The outcome was assessed by using the Modified Rankin Scale (mRS) at 3 months and whether death occurred within 3 months or not. Univariate and multivariate logistic regression analysis was used to assess the association of the PLR with the risks of poor outcome (mRS>2) and death. An individualized prediction model was established to predict poor outcome. RESULTS: Of the 741 patients, 255 (34.4%) had poor outcome, and 43 (5.8%) died. The PLR significantly increased 24 h after rtPA in patients with poor outcome and death. Logistic analysis revealed that higher PLR 24 h after rtPA was independently associated with increased risks of poor outcome and death. However, the PLR on admission was not associated with the risks of poor outcome and death. The individualized prediction model for poor outcome based on the 24-h PLR exhibited favorable discrimination (areas under the curves of the training and validation groups: 0.743 and 0.729, respectively), calibration (P > 0.05), and clinical usefulness. CONCLUSIONS: We found the PLR to be a variable that potentially predicts the risks of poor outcome and death in patients with acute ischemic stroke 24 h after rtPA; however, it cannot make the same prediction on admission. Frontiers Media S.A. 2022-09-26 /pmc/articles/PMC9549955/ /pubmed/36225933 http://dx.doi.org/10.3389/fimmu.2022.1000626 Text en Copyright © 2022 Sun, Wang, Wang, Sun, Qu, Zhu, Wang, Yan, Jin, Zhang, Yang and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sun, Ying-Ying Wang, Mei-Qi Wang, Yan Sun, Xin Qu, Yang Zhu, Hong-Jing Wang, Si-Ji Yan, Xiu-Li Jin, Hang Zhang, Peng Yang, Yi Guo, Zhen-Ni Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
title | Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
title_full | Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
title_fullStr | Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
title_full_unstemmed | Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
title_short | Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
title_sort | platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549955/ https://www.ncbi.nlm.nih.gov/pubmed/36225933 http://dx.doi.org/10.3389/fimmu.2022.1000626 |
work_keys_str_mv | AT sunyingying platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT wangmeiqi platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT wangyan platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT sunxin platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT quyang platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT zhuhongjing platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT wangsiji platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT yanxiuli platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT jinhang platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT zhangpeng platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT yangyi platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients AT guozhenni platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients |